BMS-986224

DRUG3 trials

Sponsors

Bristol-Myers Squibb

Conditions

Cardiac FailureHealthy ParticipantsHeart FailureMyocardial Failure

Phase 1

A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

TerminatedNCT03281122

Bristol-Myers SquibbHeart Failure

Start: 2017-09-22End: 2019-04-17Updated: 2021-02-25

An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants

CompletedNCT03563950

Bristol-Myers SquibbHealthy Participants

Start: 2018-06-01End: 2018-07-27Updated: 2018-08-29

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

CompletedNCT03634969

Bristol-Myers SquibbCardiac Failure, Myocardial Failure

Start: 2018-08-14End: 2019-04-30Updated: 2020-02-25

Related Papers

Cardiovascular and renal effects of apelin in chronic kidney disease: a randomised, double-blind, placebo-controlled, crossover study.

2024-10-148 citations